Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| 1 |
S&P Global
SPGI
|
+$677M |
| 2 |
AGN
Allergan plc
AGN
|
+$438M |
| 3 |
lululemon athletica
LULU
|
+$407M |
| 4 |
Qualcomm
QCOM
|
+$393M |
| 5 |
NVIDIA
NVDA
|
+$376M |
Top Sells
| 1 |
Under Armour
UAA
|
+$1.04B |
| 2 |
Abbott
ABT
|
+$758M |
| 3 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$627M |
| 4 |
Meta Platforms (Facebook)
META
|
+$516M |
| 5 |
MON
Monsanto Co
MON
|
+$453M |
Sector Composition
| 1 | Consumer Discretionary | 19.2% |
| 2 | Healthcare | 16.74% |
| 3 | Technology | 15.05% |
| 4 | Communication Services | 12.7% |
| 5 | Financials | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
501
Intel
INTC
$107B
| $3.4M | ﹤0.01% |
103,706
+328
| +0.3% | +$10.8K |
|
502
Liberty Latin America Class C
LILAK
$1.6B
| $3.38M | ﹤0.01% |
+110,426
| New | +$3.38M |
|
503
Coca-Cola
KO
$290B
| $3.36M | ﹤0.01% |
74,151
-973,246
| -93% | -$44.1M |
|
504
Evercore
EVR
$12.5B
| $3.35M | ﹤0.01% |
+75,852
| New | +$3.35M |
|
505
Baxter International
BAX
$12.4B
| $3.34M | ﹤0.01% |
+73,747
| New | +$3.34M |
|
|
ADAP
506
Adaptimmune Therapeutics
ADAP
$11.3M
| $3.28M | ﹤0.01% |
402,609
-358
| -0.1% | -$2.92K |
|
507
Berkshire Hathaway Class B
BRK.B
$1.07T
| $3.26M | ﹤0.01% |
22,505
-309
| -1% | -$44.7K |
|
508
Elevance Health
ELV
$69.4B
| $3.17M | ﹤0.01% |
24,115
+517
| +2% | +$67.9K |
|
509
PTC Therapeutics
PTCT
$4.52B
| $3.13M | ﹤0.01% |
446,000
+179,720
| +67% | +$1.26M |
|
|
TCP
510
DELISTED
TC Pipelines LP
TCP
| $3.08M | ﹤0.01% |
+53,831
| New | +$3.08M |
|
511
Waste Management
WM
$88.2B
| $3.04M | ﹤0.01% |
+45,890
| New | +$3.04M |
|
512
Bank of New York Mellon
BK
$73.4B
| $2.98M | ﹤0.01% |
76,624
-8,446
| -10% | -$328K |
|
|
ANDV
513
DELISTED
Andeavor
ANDV
| $2.82M | ﹤0.01% |
37,700
+18,332
| +95% | +$1.37M |
|
514
General Dynamics
GD
$86.8B
| $2.68M | ﹤0.01% |
19,266
+4,840
| +34% | +$674K |
|
515
American Express
AXP
$226B
| $2.62M | ﹤0.01% |
+43,137
| New | +$2.62M |
|
516
Invesco
IVZ
$9.81B
| $2.6M | ﹤0.01% |
101,807
+33,533
| +49% | +$856K |
|
517
SPDR S&P Metals & Mining ETF
XME
$2.35B
| $2.57M | ﹤0.01% |
105,241
-6,044
| -5% | -$147K |
|
518
Blackrock
BLK
$171B
| $2.47M | ﹤0.01% |
7,200
+3,206
| +80% | +$1.1M |
|
519
Markel Group
MKL
$24.4B
| $2.43M | ﹤0.01% |
2,545
-995
| -28% | -$948K |
|
520
Regenxbio
RGNX
$479M
| $2.34M | ﹤0.01% |
292,402
+14
| +0% | +$112 |
|
|
ALPN
521
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $2.27M | ﹤0.01% |
123,184
+4
| +0% | +$74 |
|
522
Stanley Black & Decker
SWK
$12.1B
| $2.23M | ﹤0.01% |
20,010
+5,176
| +35% | +$576K |
|
523
RLI Corp
RLI
$6.27B
| $2.19M | ﹤0.01% |
63,732
-992
| -2% | -$34.1K |
|
524
Danaher
DHR
$142B
| $2.09M | ﹤0.01% |
30,752
-1,815
| -6% | -$123K |
|
525
Amgen
AMGN
$151B
| $1.99M | ﹤0.01% |
+13,107
| New | +$1.99M |
|